司库奇尤单抗治疗儿童银屑病六例疗效评价

Assessment of the efficacy of Secukinumab in the treatment of six cases of childhood psoriasis

目的:评价司库奇尤单抗注射液治疗儿童银屑病的临床疗效及安全性。方法:收集2020年1月1日至2020年5月1日传统治疗方法不佳的儿童银屑病患者,在第0、1、2、3、4周进行皮下注射司库奇尤单抗150 mg,每周一次,共5次。记录患者PASI及BSA评分。结果:司库奇尤单抗共治疗6例儿童银屑病,治疗第4周时,6例患者均达到PASI 90,BSA显著降低,未出现不良反应。结论:司库奇尤单抗注射液治疗儿童银屑病安全有效。

Objective:To evaluate the clinical efficacy and safety of Secukinumab in the treatment of childhood psoriasis.Methods:The children with psoriasis who failed to respond to conventional treatments were given subcutaneous secukinumab 150 mg at week 0,1,2,3 and 4.The psoriasis area severity index(PASI)and body surface area(BSA)were assessed.Results:At week 4 of the treatment,all the 6 patients achieved PASI 90,and BSA significantly decreased,with no adverse reaction.Conclusion:Secukinumab is effective and safe for childhood psoriasis.